Navigation Links
New treatment offers hope for short-bowel syndrome patients

Bethesda, MD (July 18, 2013) A new drug, teduglutide, offers significant relief for patients with short-bowel syndrome intestinal failure who are reliant on intravenous nutrition, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. Patients with this relatively rare condition experience massive bowel loss and are unable to absorb nutrients, vitamins and water from digested foods. They rely on parenteral nutrition, or intravenous feeding, to deliver their daily nutrients.

"Short-bowel syndrome is a devastating condition, and without parenteral nutrition patients would not survive. However, this treatment method is labor-intensive, expensive and carries complications, including chronic infection, blood clots and liver failure," said Stephen J. D. O'Keefe, MD, MSc, FRCP, Division of Gastroenterology, University of Pittsburgh Medical School, PA, and lead study author. "Teduglutide, a new form of therapy, offers potential to significantly reduce intravenous nutrition dependency and improve the quality of life for patients."

Teduglutide is an injection administered once daily that helps improve intestinal absorption of fluids and nutrients, reducing the frequency and volume of parenteral nutrition.

Dr. O'Keefe and colleagues conducted a year-long trial to determine the safety, tolerability and clinical efficacy of teduglutide on patients with short-bowel syndrome. After 52 weeks, 68 percent of patients on just a low dose of teduglutide experienced lessened parenteral nutrition dependency and there was a greater than 20 percent reduction in IV-fluid requirements.

Remarkably, the study documented multiple patients who received complete independence from parenteral nutrition. These findings instill hope that short-bowel syndrome patients can achieve a significantly enhanced quality of life, free of sleep disturbances and limited social activities.

Teduglutide recently received FDA approval for individuals with short-bowel syndrome who are dependent on parenteral nutrition or intravenous therapy despite optimal medical management. There are no contraindications and no time limit on therapy. Physicians planning to prescribe the drug need to be knowledgeable in its use and potential side effects, which include gastrointestinal symptoms (abdominal pain, nausea, vomiting), headache and common cold-like symptoms. Further studies are needed to assess teduglutide's safety and efficacy long term.


Contact: Rachel Steigerwald
American Gastroenterological Association

Related biology news :

1. Molecular discovery puts cancer treatment in a new perspective
2. Which Prostate Cancers Really Need Treatment?
3. Lifesaving HIV treatment could reach millions more people following landmark study
4. Continued research needed on treatment for women with lung cancer who are never smokers
5. Artificial sweetener a potential treatment for Parkinsons disease
6. Posttraumatic stress disorder treatment: Genetic predictor of response to exposure therapy
7. Scientists identify potential drug target for treatment-resistant anemias
8. Neurochemical traffic signals may open new avenues for the treatment of schizophrenia
9. Addition of bevacizumab to initial treatment for brain tumors does not extend patients lives
10. Engineered stem cell advance points toward treatment for ALS
11. Using big data to identify prostate cancers and best treatments
Post Your Comments:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/9/2016)... 9, 2016 Paris Police ... video security solution to ensure the safety of people and ... during the major tournament Teleste, an international technology ... services, announced today that its video security solution will be ... back up public safety across the country. The system roll-out ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology: